



Oncology Drug Development: Honest Views from Academics

Faculty Presenter

Bernardo H.L. Goulart, MD, MS, Assistant Professor, University of Washington/Seattle Cancer Care Alliance; Assistant Member, Fred Hutchinson Cancer Center, Seattle, WA, USA

Scholar Summary

*Authored by **Juan Pablo Alderuccio, MD**, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA*

Dr. Bernardo H.L. Goulart gave an outstanding talk about the development of oncologic drugs in academia. He initiated his talk by showing the number of drugs approved and the source of patents over the last few years (academia vs. pharmaceutical vs. biotechnology companies). He elegantly discussed his view about value in academia and survival benefit of oncologic drugs approved over the last decade. He correlated the marginal survival benefit of some of these drugs with their excessive costs and the consequences of these costs to the American health system. His discussions about creating value with financially adaptive clinical trials and the ASCO perspective in defining clinically meaningful outcomes for clinical trials were especially noteworthy.

Dr. Goulart provided very valuable tips for a successful career in drug development and how to set up an extraordinary program in academia. He also provided a meaningful explanation of how investigator initiated, industry-sponsored and cooperative group clinical trials will impact our careers with their pros and cons.

Most importantly, he provided a real world perspective in authorship negotiation, accrual process, time consuming, and feasibility issues for each type of clinical trial.